更好地控制餐后血糖实现全面达标礼来秦贵军.pptVIP

血糖控制指标 空腹血糖 餐后血糖 糖化血红蛋白(HbA1c) 血糖稳定性 谢谢 * * * 优泌乐50因为含有50%的速效赖脯胰岛素优泌乐和50%的精蛋白锌赖脯胰岛素优泌乐长效，在餐后血糖控制方面表现更佳。 * * 在治疗效果上，优泌乐50组已有非常明显的效果，那安全性如何呢？ 值得高兴的是，虽然优泌乐50TID的方案比人胰岛素30/70BID的方案注射次数要多1次，但在低血糖方面两组无明显差异，这让各位可更放心地使用优泌乐50TID的方案。 * 入组23名糖尿病患者和10名正常健康对照。所有糖尿病患者分别接受优泌乐50/优泌乐25/优泌林30/70治疗至少10小时以上，观察血糖控制情况。结果见到，优泌乐50具有较好的控制血糖波动的作用。 * 优泌乐50有效改善日内血糖波动 In order to decrease the risk of diabetes-related complications, individuals with diabetes should receive intensive and effective treatment for all metabolic disturbances, including hyperglycemia.However, data from several studies indicate that treatment of hyperglycemia may be more difficult to achieve relative to management of dyslipidemia and hypertension. For example, in the Steno-2 study, only 15% of individuals with diabetes assigned intensive treatment achieved their HbA1c goal of ?6.5%, compared with notably more individuals achieving goals for cholesterol (72%) or triglyceride (58%) levels or systolic/diastolic blood pressure (46% and 72%, respectively). This may be caused by a number of factors, for example: the complexity of managing hyperglycemia relative to dyslipidemia or hypertension differences in the efficacy of available antidiabetic medications relative to lipid-lowering agents or antihypertensive drugs greater public awareness and acceptance of the general health benefits of lowering lipids and blood pressure relative to glycemic control. Gaede P, et al. N Engl J Med 2003; 348:383–393. * 目的： 研究在糖尿病控制、管理及并发症状况之间的关系，由此进一步提供评价糖尿病管理质量的方法 研究对象： 选取遍布全国的已接受治疗至少12个月的糖尿病患者 1998年纳入了2246例患者，2006年纳入了2702例患者 数据收集： 回顾性复查患者的病历，包括问诊和实验室检查结果 OBJECTIVE: To describe and compare the differences in subject characteristics, glycaemic control, diabetes complications, and treatment between 1998 and 2006 in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Subjects who had been registered for diabetes care at the diabetes clinic (defined as any clinic treating over 100 patients/month) for over 12 months were enrolled.